ACC.23 Scientific Sessions 2023
Phase 2b data show benefits of oral MK-0616 in hypercholesterolaemia
The experimental oral PCSK9 inhibitor, MK-0616, has significantly reduced LDL-C in all four doses tested compared to placebo (p<0.001), with near-complete efficacy achieved by two weeks and effects persistent over eight weeks of treatment.1 In the Phase 2b study in 381 patients with hypercholesterolaemia, placebo-adjusted…
read more »
YELLOW III supports aggressive lipid lowering to reduce plaque progression
Intensive lipid lowering with evolocumab for 26 weeks significantly increases minimal fibrous cap thickness (FCT) of coronary plaque in patients with stable coronary artery disease on maximally tolerated statins, and reduces maximal lipid-core burden index within 4 mm (maxLCBI4mm) and atheroma volume. These were the…
read more »
CLEAR Outcomes shows 13% reduction in CV events with bempedoic acid
Among statin-intolerant patients with or at high risk of cardiovascular (CV) disease, bempedoic acid reduced the risk of major adverse cardiovascular events (MACE) by 13% at a median 40.6 months follow-up, according to results of the CLEAR Outcomes trial presented at ACC.23 and published in…
read more »
Olpasiran reduces Lp(a) irrespective of baseline Lp(a)
A further analysis of data from the Phase 2 OCEAN(a)-DOSE study has shown that the siRNA, olpasiran, reduced Lp(a) irrespective of baseline Lp(a) concentration in participants with atherosclerotic cardiovascular disease (ASCVD) and Lp(a) >150 nmol/L. Median baseline Lp(a) concentration was 260.3 (IQR 198.1-352.4) nmol/L. In…
read more »
